TherapeuticsMD Inc (TXMD) Receives $17.50 Average PT from Analysts

TherapeuticsMD Inc (NYSEMKT:TXMD) has been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $17.50.

Several analysts have weighed in on the company. BidaskClub cut TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday. Morgan Stanley assumed coverage on TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. raised TherapeuticsMD from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 11th.

TRADEMARK VIOLATION WARNING: “TherapeuticsMD Inc (TXMD) Receives $17.50 Average PT from Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

TherapeuticsMD (TXMD) traded up 0.21% during mid-day trading on Thursday, hitting $4.86. 1,610,160 shares of the company were exchanged. The company’s market cap is $991.57 million. The stock’s 50 day moving average is $4.87 and its 200-day moving average is $4.87. TherapeuticsMD has a 12-month low of $4.54 and a 12-month high of $5.35.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.

Leave a Reply